Innoviva (INVA) Long-Term Investments (2012 - 2026)
Innoviva's (INVA) quarterly Long-Term Investments came in at $413.1 million in Q1 2026, up 41.9% YoY from $291.1 million in Q1 2025, and up 2.12% on a QoQ basis from $404.5 million in Q4 2025.
Analysis
Innoviva (INVA) Long-Term Investments (2012 - 2026) Analysis & Trends
Innoviva (INVA) has 11 years of Long-Term Investments data on file, last reported at $413.1 million in Q1 2026.
- Quarterly Long-Term Investments rose 41.9% year-over-year to $413.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $413.1 million (up 41.9% YoY) and the FY2025 annual result came in at $404.5 million, up 18.39% from the prior year.
- Long-Term Investments climbed to $413.1 million in Q1 2026, from $404.5 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $544.4 million in Q1 2022 to a low of $291.1 million in Q1 2025.
- A 5-year average of $412.0 million and a median of $413.1 million in 2026 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2025 — Long-Term Investments slumped 38.91% — and 2026, when it soared 41.9%.
- Tracing INVA's Long-Term Investments over 5 years: stood at $363.9 million in 2022, then grew by 22.14% to $444.4 million in 2023, then decreased by 23.12% to $341.7 million in 2024, then climbed by 18.39% to $404.5 million in 2025, then climbed by 2.12% to $413.1 million in 2026.
- The last three Long-Term Investments figures came in at $413.1 million (Q1 2026), $404.5 million (Q4 2025), and $343.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | 441.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 441.31 Mn |
| Mar 31, 2026 | 413.08 Mn |
| Dec 31, 2025 | 404.50 Mn |
| Sep 30, 2025 | 343.79 Mn |
| Jun 30, 2025 | 297.28 Mn |
| Mar 31, 2025 | 291.10 Mn |
| Dec 31, 2024 | 341.66 Mn |
| Sep 30, 2024 | 434.17 Mn |
| Jun 30, 2024 | 444.66 Mn |
| Mar 31, 2024 | 476.55 Mn |
| Dec 31, 2023 | 444.43 Mn |
| Sep 30, 2023 | 422.49 Mn |
| Jun 30, 2023 | 397.94 Mn |
| Mar 31, 2023 | 400.89 Mn |
| Dec 31, 2022 | 363.86 Mn |
| Sep 30, 2022 | 489.11 Mn |
| Jun 30, 2022 | 494.10 Mn |
| Mar 31, 2022 | 544.44 Mn |
| Dec 31, 2021 | 483.85 Mn |
| Sep 30, 2021 | 507.12 Mn |